UNSPSC 51313219: Pimethixene maleate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19NS.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U22U244M9X, chemically known as thioxanthene, 9-(1-methyl-4-piperidylene)-, maleate but more generally known as pimethixene maleate, which bears US NIH Compound Identifier 5702167. Most nations, for tariff and trade purposes, schedule pimethixene maleate under HS 29349990 and SITC 51579. As of Q4 2014, PIMETHIXENE MALEATE remains US FDA's Preferred Term for this commodity.

Pimethixene maleate bears US NLM identifiers UMLS ID C3273580 and NCI Concept Code C97703. SMILES: CN1CCC(=C2C3CCCCC3SC4C2CCCC4)CC1.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51313219 Pimethixene maleate is a Commodity code nominally designating a specific pharmaceutical compound, but recent state and local solicitations tagged under this code show little alignment with pimethixene itself. Instead, the code appears in procurement activity for naloxone products, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs that span naloxone and over-the-counter product sourcing. State and local governments buying under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work involves competitive procurement of finished pharmaceutical products—naloxone in particular—with quarterly or ongoing distribution requirements, compliance with federal pharmacy regulations (cGMP, DSCSA, FDA), and insurance and E-Verify mandates for vendors.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to explore direct-to-manufacturer prescription programs that could support state pharmacy benefit objectives without traditional pharmacy benefit manager intermediaries. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with proposals due March 26, 2026, and awards effective July 1, 2026. The code shows activity among health departments, state procurement offices, and cooperative purchasing vehicles, but the mismatch between the nominal pimethixene designation and actual solicitations for naloxone and broad pharmaceutical product lines suggests this code may be incorrectly applied or represents a taxonomic overlap issue in state and local systems.